# syapse

Syapse is on a mission to enable healthcare providers to deliver the best care to every cancer patient through precision medicine

We are a real-world evidence company that partners with health systems, life sciences companies, and regulators to drive better outcomes for people with cancer around the world. Syapse integrates, standardizes, and normalizes clinical and genomic data in a centralized platform that can be utilized by healthcare providers, researchers, executives, and others to advance the practice of precision medicine.

By bringing together leading healthcare innovators into a unified ecosystem, we have built an international data sharing network that informs patient care and accelerates drug development.

Health Systems
Get the Care Right

Provide high-quality care for patients, leveraging insights from the Syapse Learning Health Network.

SYAPSE-FACILITATED COLLABORATIONS

clinical and molecular data

network data

insights

clinical and molecular data

network data

insights

syapse

insights

validated frameworks

insights

HEALTH SYSTEM PARTNERS

Life Sciences
Get the Therapy Right

Partner to expand access to precision medicine and build evidence on clinical impact.

Partner to develop and advance standards for clinical and regulatory use of real-world data.

Regulators
Get the Evidence Right

## Answer Real-World Questions

Example clinical use case

A physician has an upcoming case review for a 70-year old patient with stage IV NSCLC who has progressed on targeted therapy. What treatments have patients with similar clinical and genomic profiles received in the real world?

Example research use case

How does the survival of NSCLC patients who received pembrolizumab monotherapy first line compare to the survival of patients who received a combination of pembrolizumab and a platinum-based chemotherapy regimen first line?

The Syapse Approach

By connecting with electronic health records (EHRs), data warehouses, registries, and other sources, Syapse is able to extract complex clinical data such as diagnosis and staging, pathology and radiology reports, treatment and outcomes, demographics, and more. Syapse also captures genomic and other molecular test results as structured data through direct integration with molecular diagnostics labs. Additionally, Syapse applies a data quality improvement framework that uses a combination of manual abstraction by highly trained medical data professionals and machine learning to create a comprehensive patient record.

DATA COLLECTION ACROSS MULTIPLE SOURCES	DATA ACQUISITION INFRASTRUCTURE	DATA STRUCTURING & NORMALIZATION	DATA QUALITY IMPROVEMENT	INSIGHTS DELIVERY
Molecular and health system clinical data	Interoperability and manual abstraction	Knowledge bases and mapping	Manual abstraction and machine learning	

The Syapse Difference

Our advantage is powered by a decade of partnership with the Syapse Learning Health Network of health systems, biopharmaceutical companies, regulators, and advocacy groups. Our data strategy is built around full longitudinality, continuous updates to ensure recency, and ingestion of both oncology and non-oncology data to fully contextualize patients throughout their care journeys. Common data standards and rigorous privacy and security measures allow Syapse partners to share valuable insights across the network.

CASE STUDY

Identify candidates for a newly approved targeted therapy

Syapse delivered a list of patients who had solid tumors with NTRK gene fusions potentially eligible for treatment with larotrectinib.

CASE STUDY

Streamline clinical trial recruitment

Syapse found 19 patients at four partner health systems and facilitated talks with a life sciences partner that led to at least one new trial site being opened.

CASE STUDY

Reduce the burden of molecular tumor board case preparation

Syapse saved research coordinators nearly eight hours per week with Syapse Oncology molecular tumor board software and service offerings.

About Syapse

Syapse was founded in 2008 for a single purpose: to ensure that every patient has access to precision cancer care. Since then, we have expanded to new locations in San Francisco, Philadelphia, South Korea, and Japan.